Takeda Pharmaceutical Company

Tome Biosciences Appoints Industry Veteran Daniel Curran, MD, to its Board of Directors

Retrieved on: 
Tuesday, January 30, 2024
PGI, Genetics, School, Head, MD, Patient, Biotechnology, Investment, Corporation, MBA, Takeda, SVP, Vice president, Drug development, Acquisition, Hematology, Genetic code, Takeda Oncology, Takeda Pharmaceutical Company, University, Millennium, Pharmaceutical industry

WATERTOWN, Mass., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, announces the appointment of Daniel Curran, MD, to its Board of Directors.

Key Points: 
  • WATERTOWN, Mass., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Tome Biosciences, Inc., the programmable genomic integration (PGI) company, announces the appointment of Daniel Curran, MD, to its Board of Directors.
  • Dr. Curran was most recently Head of Rare Genetics and Hematology at Takeda Pharmaceuticals.
  • “Dan has a storied corporate and drug development career, stretching from his tenure at Millennium through to leadership at Takeda.
  • Notably, Dan oversaw the integration of Shire after its acquisition by Takeda, then leading development and execution of Takeda’s rare disease portfolio strategy,” said Rahul Kakkar, MD, President and CEO of Tome Biosciences.

Proniras Corporation Secures New Series B Financing and Names New Board Members to Support Phase 1 Study of Novel Treatment for Opiate Withdrawal

Retrieved on: 
Thursday, February 1, 2024
Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, ARCH Venture Partners, Senior, Corporation, GSK plc, MedImmune, Takeda Pharmaceutical Company, Knowledge, Eli Lilly and Company, Opioid, WRF, VBI Vaccines, AstraZeneca, Acquisition, Development, Epilepsy, Public, Growth, General counsel, Vilya, Corporate development, Patient, Venture round, LP, Research, Trial of the century, ARCH, Therapy, DSM-IV codes, Series

PRN-001-01 (tezampanel) is a novel small molecule compound that will be the first parenteral therapeutic to be evaluated for the treatment of symptoms associated with opiate withdrawal in a Phase 1 clinical study.

Key Points: 
  • PRN-001-01 (tezampanel) is a novel small molecule compound that will be the first parenteral therapeutic to be evaluated for the treatment of symptoms associated with opiate withdrawal in a Phase 1 clinical study.
  • In conjunction with the Series B financing, Proniras has appointed Steven Gillis, Ph.D., as Chairman and Atul Saran as an independent member to the Company’s Board of Directors.
  • "Their wealth of knowledge and industry experience will be instrumental in guiding Proniras through its next phase of growth.
  • We look forward to their leadership and contributions as we continue to advance Proniras through the next stages of product development."

Global Narcolepsy Drugs Market Research Report 2024: Pipeline Analysis, Key Company Profiles and Recent Developments 2023-2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 30, 2024
General Health, Pharmaceutical, Health, Narcolepsy, Jazz Pharmaceuticals, CIII, FDA, Central nervous system, Somnolence, Consciousness, Quality of life, DSM-IV codes, Mazindol, Takeda Pharmaceutical Company, Tobacco, Organization, Cataplexy, EDS, Prevalence, American Academy, CNS, Selective serotonin reuptake inhibitor, Growth, Patient, Diagnosis, Marketing, Disease, U.S. FDA, NINDS, Research, Therapy, Teva Pharmaceuticals, Investment, Avadel Pharmaceuticals, European Medicines Agency, Pharmaceutical industry

The "Global Narcolepsy Drugs Market (By Therapeutic Type, Disease Type, End User, Regional Analysis), Pipeline Analysis, Key Company Profiles and Recent Developments - Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Narcolepsy Drugs Market (By Therapeutic Type, Disease Type, End User, Regional Analysis), Pipeline Analysis, Key Company Profiles and Recent Developments - Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global narcolepsy drugs market has witnessed significant growth in recent years owing to the rising prevalence of narcolepsy and increased awareness about the condition.
  • Latin America and Middle East & Africa are competing closely to grab the maximum share of the global narcolepsy drugs market.
  • Global Narcolepsy Drugs Market - Key Company Profiles, Recent Developments, Financial Insights

Regenerative Medicine Market Worth $49.0 Billion | MarketsandMarkets™.

Retrieved on: 
Friday, January 26, 2024
Conditional sentence, Artificial intelligence, Dermatology, Market development, HSCT, Regenerative medicine, Research, Neurology, Pulse, Ophthalmology, Amgen, Smith & Nephew, Novartis, Cancer, Integration, Gilead Sciences, Investment, Tissue engineering, Takeda Pharmaceutical Company, Biogen, Transplant, Prevalence, DSM-IV codes, Growth, Veterinary medicine

The cell therapy segment accounted for the largest share of the regenerative medicine market in 2022.

Key Points: 
  • The cell therapy segment accounted for the largest share of the regenerative medicine market in 2022.
  • In 2022, the musculoskeletal disorders segment accounted for the largest share of the global regenerative medicine market.
  • •  Market Development: Comprehensive information about lucrative markets – the report analyses the regenerative medicine market across varied regions.
  • •  Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the regenerative medicine market.

Plexium Announces Appointment of Michael Martin, Ph.D. as President and CEO

Retrieved on: 
Tuesday, January 16, 2024
SMARCA2, Research, Biology, Analytical chemistry, Sanofi, TPD, SAN, University, Business development, Cancer, Evaluation, Takeda Pharmaceutical Company, Medicinal chemistry, CDK2, Pharmaceutical industry

SAN DIEGO, Jan. 16, 2024 /PRNewswire/ -- Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Michael Martin, Ph.D. as President and Chief Executive Officer, and a member of the Board of Directors.

Key Points: 
  • SAN DIEGO, Jan. 16, 2024 /PRNewswire/ -- Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Michael Martin, Ph.D. as President and Chief Executive Officer, and a member of the Board of Directors.
  • "I look forward to working with Mike to advance our clinical-stage pipeline and progressing more TPD programs against important cancer targets into the clinic."
  • I am excited to lead Plexium and continue to build a leading TPD company focused on improving patients' lives."
  • Dr. Martin joined Takeda in 2012 and prior to his most recent role, he was President of Takeda Ventures, Inc., Takeda's corporate venture capital company.

USAntibiotics Appoints Eric Wesoloski Vice President of Quality and Regulatory Affairs

Retrieved on: 
Thursday, January 11, 2024
Biotechnology, Pharmaceutical, Health, Transcoding, Amoxicillin, Pharmacovigilance, Food and Drug Administration, Food, Gan, FDA, Takeda Pharmaceutical Company, Pharmaceutical industry

USAntibiotics , the sole licensed American manufacturer of penicillin-based Amoxicillin and Amoxil Clavulanate, the life-saving antibiotics commonly known as Amoxil® and Augmentin®, today announced the appointment of Eric Wesoloski to the position of vice president of quality and regulatory affairs.

Key Points: 
  • USAntibiotics , the sole licensed American manufacturer of penicillin-based Amoxicillin and Amoxil Clavulanate, the life-saving antibiotics commonly known as Amoxil® and Augmentin®, today announced the appointment of Eric Wesoloski to the position of vice president of quality and regulatory affairs.
  • In this role, Wesoloski leads all aspects of quality assurance and control, compliance, regulatory affairs and pharmacovigilance related to the manufacturing, packaging, distribution and post-marketing requirements for the company’s antibiotics.
  • With more than 30 years in the life sciences industry, Wesoloski’s experience spans markets that include biologics, nutraceuticals, medical devices and pharmaceuticals.
  • “We are pleased to welcome Eric Wesoloski to USAntibiotics as vice president of quality and regulatory affairs,” said Patrick Cashman, president, USAntibiotics.

BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2023 Unaudited Revenue

Retrieved on: 
Monday, January 8, 2024
Takeda Pharmaceutical Company, CGT, BLFS, Video game

BOTHELL, Wash., Jan. 8, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced 2023 fourth quarter and full year preliminary unaudited revenue.

Key Points: 
  • BOTHELL, Wash., Jan. 8, 2024 /PRNewswire/ -- BioLife Solutions , Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced 2023 fourth quarter and full year preliminary unaudited revenue.
  • We are pleased to announce preliminary results for the fourth quarter, showing an 11% sequential increase in our core cell processing revenue which came in ahead of our expectations.
  • Preliminary and unaudited revenue for the fourth quarter of 2023 was $32.7 million, a decrease of 26% from $44.3 million for the fourth quarter of 2022.
  • Preliminary and unaudited revenue for the full year 2023 was $143.3 million, a decrease of 11% from $161.8 million for 2022.

Narcolepsy Drugs Market, Size, Global Forecast 2024-2030: Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis - ResearchAndMarkets.com

Retrieved on: 
Friday, December 29, 2023
Health, Pharmaceutical, Novartis, Teva Pharmaceuticals, Quality of life, Sodium oxybate, Food, Risk, Drug development, Takeda Pharmaceutical Company, Roche, Research, Cataplexy, FDA, Instability, Prevalence, NINDS, Incidence, Mazindol, GHB, Stimulant, EDS, NMPA, Narcolepsy, Tobacco, DSM-IV codes, Investment, Patient, Diagnosis, Organization, Somnolence, Neurological disorder, Pharmaceutical industry

The "Narcolepsy Drugs Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Narcolepsy Drugs Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The Global Narcolepsy Drugs Market is poised for substantial growth, with a projected value of US$5.95 billion by 2030
    Several factors contribute to the expansion of the narcolepsy drugs market.
  • The Narcolepsy Drugs Market is expected to grow steadily, with a compound annual growth rate (CAGR) of 8.01% from 2023 to 2030.
  • Combined, these elements make the U.S. narcolepsy drugs market a leader in global healthcare.

Stem Cell Therapy Market Worth $615 Million | MarketsandMarkets

Retrieved on: 
Tuesday, December 12, 2023
Microsoft Exchange Server, DSM-IV codes, Research, Prevalence, Takeda Pharmaceutical Company, IND, RTI Surgical, Investment, NuVasive, Market development, Patient, ALS, PVT, COVID-19, Stem cell, Master of ceremonies, US FDA, Technical, Cancer, Pulse, RESEARCH, Growth, Embryonic stem cell, Ethics, Adipose tissue, Silk, Veterinary medicine, Pharmaceutical industry

The global stem cell therapy market is segmented into adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources.

Key Points: 
  • The global stem cell therapy market is segmented into adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources.
  • Stem Cell Therapy Market Dynamics:
    Key Market Players of Stem Cell Therapy Industry:
    The stem cell therapy market is competitive, with a small number of players competing for market shares.
  • Stem Cell Therapy Market - Key Benefits of Buying the Report:
    The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell therapy market and its subsegments.
  • The report provides insights on the following pointers:
    Analysis of key drivers (Increased funding for stem cell research, rise in collabrations and partnerships is likley to uplift the market growth, Increasing clinical trials for stem cell based-therapies), restraints ( Ethical concerns related to embryonic stem cells, high cost of cell-based research), opportunities (The emergence of iPSCs as an alternative to ESCs, growing demand for stem cell and gene therapy) and challenges (Technical limitations) are influencing the growth of stem cell therapy market.

Stem Cell Therapy Market Worth $615 Million | MarketsandMarkets

Retrieved on: 
Tuesday, December 12, 2023
Microsoft Exchange Server, DSM-IV codes, Research, Prevalence, Takeda Pharmaceutical Company, IND, RTI Surgical, Investment, NuVasive, Market development, Patient, ALS, PVT, COVID-19, Stem cell, Master of ceremonies, US FDA, Technical, Cancer, Pulse, RESEARCH, Growth, Embryonic stem cell, Ethics, Adipose tissue, Silk, Veterinary medicine, Pharmaceutical industry

The global stem cell therapy market is segmented into adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources.

Key Points: 
  • The global stem cell therapy market is segmented into adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources.
  • Stem Cell Therapy Market Dynamics:
    Key Market Players of Stem Cell Therapy Industry:
    The stem cell therapy market is competitive, with a small number of players competing for market shares.
  • Stem Cell Therapy Market - Key Benefits of Buying the Report:
    The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell therapy market and its subsegments.
  • The report provides insights on the following pointers:
    Analysis of key drivers (Increased funding for stem cell research, rise in collabrations and partnerships is likley to uplift the market growth, Increasing clinical trials for stem cell based-therapies), restraints ( Ethical concerns related to embryonic stem cells, high cost of cell-based research), opportunities (The emergence of iPSCs as an alternative to ESCs, growing demand for stem cell and gene therapy) and challenges (Technical limitations) are influencing the growth of stem cell therapy market.